Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
(Values in U.S. thousands)
| 01-2026 | 10-2025 | 07-2025 | 04-2025 | 01-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,547 | 1,244 | 1,495 | 1,910 | 1,053 |
| Marketable Securities | 12,655 | 13,930 | 14,534 | 13,687 | 16,202 |
| TOTAL | $15,050 | $15,887 | $17,449 | $16,766 | $18,686 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 183 | 193 | 202 | 211 | 220 |
| TOTAL | $183 | $193 | $202 | $211 | $220 |
| Total Assets | $15,233 | $16,080 | $17,651 | $16,977 | $18,906 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 148 | 165 | 276 | 284 | 600 |
| Accrued Expenses | 1,046 | 1,761 | 1,751 | 1,566 | 1,363 |
| TOTAL | $1,236 | $1,967 | $2,066 | $1,887 | $1,999 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 171 | 190 | 196 | 207 | 223 |
| TOTAL | $151 | $163 | $174 | $184 | $194 |
| Total Liabilities | $1,387 | $2,130 | $2,240 | $2,071 | $2,193 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 33,528 | 33,377 | 32,917 | 32,211 | 32,197 |
| Common Shares | 335 | 330 | 328 | 322 | 322 |
| Retained earnings | -254,242 | -251,677 | -248,982 | -246,724 | -243,934 |
| Other shareholders' equity | -1,231 | -1,211 | -1,184 | -1,162 | -1,145 |
| TOTAL | $13,846 | $13,950 | $15,411 | $14,906 | $16,713 |
| Total Liabilities And Equity | $15,233 | $16,080 | $17,651 | $16,977 | $18,906 |